JPH09110677A - Aerosol preparation - Google Patents
Aerosol preparationInfo
- Publication number
- JPH09110677A JPH09110677A JP8206774A JP20677496A JPH09110677A JP H09110677 A JPH09110677 A JP H09110677A JP 8206774 A JP8206774 A JP 8206774A JP 20677496 A JP20677496 A JP 20677496A JP H09110677 A JPH09110677 A JP H09110677A
- Authority
- JP
- Japan
- Prior art keywords
- propellant
- aerosol
- menthol
- weight
- pruritus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003380 propellant Substances 0.000 claims abstract description 14
- -1 polyoxyethylene Polymers 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940041616 menthol Drugs 0.000 claims abstract description 9
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 6
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 6
- 229960000846 camphor Drugs 0.000 claims abstract description 6
- 229930008380 camphor Natural products 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000012046 mixed solvent Substances 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 8
- 239000011550 stock solution Substances 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 abstract description 17
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 230000003111 delayed effect Effects 0.000 abstract description 3
- 241000238631 Hexapoda Species 0.000 abstract 1
- 230000007803 itching Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000006877 Insect Bites and Stings Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000001589 sorbitan tristearate Substances 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 229960004129 sorbitan tristearate Drugs 0.000 description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、虫刺されや水虫などに
よる痒みに対する鎮痒効果の優れたエアゾール剤に関す
る。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an aerosol agent having an excellent antipruritic effect against pruritus caused by insect bites and athlete's foot.
【0002】[0002]
【従来の技術】虫刺されによる皮膚反応として、痒みや
発赤があり、その反応は刺咬数分後〜1時間後の即時反
応と十数時間〜1日後の遅延反応がある。このうち、遅
延反応の痒みについては、局所麻酔剤や鎮痒剤を配合し
た一般的な軟膏などの薬剤の塗布により抑えることがで
きる。これに対して即時反応の痒みについては、上記薬
剤の塗布では勿論、エタノールなどの原液成分の蒸発に
よる冷却や、単なる噴射剤の噴霧による冷却でも充分に
抑えることができなかった。2. Description of the Related Art Skin reactions caused by insect bites include itching and redness, and there are an immediate reaction several minutes to one hour after the bite and a delayed reaction after ten and several hours to one day. Among them, the itching of delayed reaction can be suppressed by applying a drug such as a general ointment containing a local anesthetic or an antipruritic. On the other hand, itching of the immediate reaction could not be sufficiently suppressed not only by applying the above-mentioned chemicals but also by cooling by evaporation of the stock solution components such as ethanol or simply by spraying a propellant.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、虫刺
されによる即時反応の痒みや水虫の痒みに対する鎮痒効
果に優れた製剤を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a preparation having an excellent antipruritic effect against itching of immediate reaction caused by insect bites and pruritus of athlete's foot.
【0004】[0004]
【課題を解決するための手段】本発明者らは鋭意研究を
進めた結果、ある特定の界面活性剤にメントール及びカ
ンフルを一定の割合で配合したエアゾール剤が、前記課
題を解決することを見いだし、本発明を完成した。すな
わち本発明は、水と低級アルコールとの混合溶媒に、次
の(A)〜(C)の成分を配合した原液及び噴射剤から
なるエアゾール剤である。 (A)ポリオキシエチレンソルビタン脂肪酸エステル類
及びソルビタン脂肪酸エステル類からなる群より選ばれ
る界面活性剤1種または2種以上 (B)メントール0.5〜8重量% (C)メントール1重量部に対して1〜0.5重量部の
カンフル。As a result of intensive studies, the inventors of the present invention found that an aerosol formulation containing menthol and camphor at a certain ratio in a specific surfactant can solve the above-mentioned problems. The present invention has been completed. That is, the present invention is an aerosol agent comprising a stock solution and a propellant in which the following components (A) to (C) are mixed in a mixed solvent of water and a lower alcohol. (A) one or more surfactants selected from the group consisting of polyoxyethylene sorbitan fatty acid esters and sorbitan fatty acid esters (B) menthol 0.5 to 8 wt% (C) to 1 part by weight of menthol 1 to 0.5 parts by weight camphor.
【0005】本発明において用いる、ポリオキシエチレ
ンソルビタン脂肪酸エステル類及びソルビタン脂肪酸エ
ステル類からなる群より選ばれる界面活性剤とは、原液
調製時に室温においてペースト状または半固形状となる
ものであり、ポリオキシエチレン(6)ソルビタンモノ
ステアレート単独あるいはポリオキシエチレン(20)
ソルビタンモノステアレート、ポリオキシエチレン(2
0)ソルビタントリステアレート及びソルビタンモノス
テアレートの混合物が好ましい。これらの配合量は0.
5〜8重量%好ましくは0.5〜4重量%である。The surfactant used in the present invention, which is selected from the group consisting of polyoxyethylene sorbitan fatty acid esters and sorbitan fatty acid esters, is a paste or a semisolid at room temperature when preparing a stock solution. Oxyethylene (6) sorbitan monostearate alone or polyoxyethylene (20)
Sorbitan monostearate, polyoxyethylene (2
0) Mixtures of sorbitan tristearate and sorbitan monostearate are preferred. The blending amount of these is 0.
5 to 8% by weight, preferably 0.5 to 4% by weight.
【0006】また、溶媒は水と低級アルコールの混合物
であるが、その重量比が30:70〜70:30の範囲
のものが好ましい。噴射剤には液化ガスを用いるが、液
化ガスとしては、ジメチルエーテル、n−ブタン、イソ
ブタン、プロパンあるいはこれらの混合物を用いること
ができる。この中でもジメチルエーテルを80重量%以
上含有する噴射剤が好ましい。噴射剤の配合量は製剤全
体の40〜80重量%、好ましくは50〜70重量%で
ある。Further, the solvent is a mixture of water and a lower alcohol, and the weight ratio thereof is preferably in the range of 30:70 to 70:30. A liquefied gas is used as the propellant, and dimethyl ether, n-butane, isobutane, propane or a mixture thereof can be used as the liquefied gas. Among these, a propellant containing 80% by weight or more of dimethyl ether is preferable. The compounding amount of the propellant is 40 to 80% by weight, preferably 50 to 70% by weight, based on the whole preparation.
【0007】なお、本発明のエアゾール剤には、鎮痒剤
や抗真菌剤に通常配合される成分、例えば鎮痒薬(クロ
タミトン、イクタモール、モクタモール、チモール酸
等)、抗真菌薬(トルナフテート、硝酸ミコナゾール
等)、抗ヒスタミン薬(ジフェンヒドラミン、塩酸ジフ
ェンヒドラミン、塩酸イソチペンジル、マレイン酸クロ
ルフェニラミン等)、局所麻酔薬(リドカイン、塩酸ジ
ブカイン等)、殺菌剤(ヨウ化カリウム、グルコン酸ク
ロルヘキシジン、アクリノール、塩化ベンザルコニウム
等)、消炎剤(アラントイン、グリチルレチン酸、サリ
チル酸メチル等)、抗酸化剤(ジブチルヒドロキシトル
エン等)、溶解補助剤(アジピン酸ジイソプロピル、ミ
リスチン酸イソプロピル、乳酸、水酸化ナトリウム
等)、香料等を本発明の効果を損なわない範囲で配合す
ることができる。In the aerosol composition of the present invention, the components usually contained in antipruritic agents and antifungal agents, for example, antipruritic agents (crotamiton, ictamol, moctamol, thymolic acid, etc.), antifungal agents (tornaftate, miconazole nitrate, etc.) ), Antihistamines (diphenhydramine, diphenhydramine hydrochloride, isothipendyl hydrochloride, chlorpheniramine maleate, etc.), local anesthetics (lidocaine, dibucaine hydrochloride, etc.), bactericides (potassium iodide, chlorhexidine gluconate, acrinol chloride, benzalkonium chloride) Etc.), anti-inflammatory agents (allantoin, glycyrrhetinic acid, methyl salicylate, etc.), antioxidants (dibutylhydroxytoluene, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, lactic acid, sodium hydroxide, etc.), fragrances, etc. Effect of invention It can be added in amounts not detrimental to the.
【0008】本発明のエアゾール剤は、噴射剤以外の成
分を加温、混合、撹拌して溶解あるいは均一に分散させ
て液剤を調製した後、この液剤をエアゾール容器に噴射
剤と共に充填することにより製造することができる。The aerosol of the present invention is prepared by heating, mixing, stirring and dissolving or uniformly dispersing components other than the propellant to prepare a liquid, and then filling the liquid with the propellant in an aerosol container. It can be manufactured.
【0009】[0009]
【発明の効果】以上の組成のエアゾール剤にすることに
より、エアゾール剤噴射時に原液がシャーベット状とな
り、単にアルコールや噴射剤を噴射したとき以上の冷却
効果が得られ、さらにメントールとカンフルを特定の比
率で配合することにより特異的な鎮痒効果効果が得られ
る。従って、本発明により、虫刺されによる即時反応の
痒みや水虫の痒みを即時的かつ持続的に和らげるエアゾ
ール剤を提供することが可能となった。EFFECTS OF THE INVENTION By using the aerosol composition having the above composition, the stock solution becomes sherbet-like at the time of spraying the aerosol, and the cooling effect more than that obtained by simply spraying alcohol or propellant can be obtained, and further menthol and camphor can be specified. A specific antipruritic effect can be obtained by mixing in a ratio. Therefore, according to the present invention, it is possible to provide an aerosol agent which can immediately and continuously relieve the itch of immediate reaction due to insect bites and the itch of athlete's foot.
【0010】[0010]
【実施例】以下、実施例及び試験例を挙げて、本発明を
更に詳細に説明する。 実施例1原液 成分 配合量(g) リドカイン 0.6 ジフェンヒドラミン 0.3 メントール 0.6 カンフル 0.6 ニッコールTS−10[ホ゜リオキシエチレン(20)ソルヒ゛タン モノステアレートの商品名] 0.9 ニッコールTS−30[ホ゜リオキシエチレン(20)ソルヒ゛タン トリステアレートの商品名] 0.6 ニッコールSS−10[ソルヒ゛タンモノステアレートの商品名] 0.9 エチルアルコール 10.5 精製水 全30ml 噴射剤 ジメチルエーテル 70ml 原液の各成分を加温、混合、撹拌して均一にし原液を調
製した後、この原液をエアゾール容器に噴射剤と共に充
填し、エアゾール剤を製造した。EXAMPLES The present invention will be described in more detail below with reference to examples and test examples. Example 1 stock Ingredients Amounts (g) Lidocaine 0.6 Diphenhydramine 0.3 Menthol 0.6 Camphor 0.6 Nikkol TS-10 [polyoxyethylene (20) Soruhi Keypad tradename monostearate] 0.9 Nikkor TS -30 [Product name of polyoxyethylene (20) sorbitan tristearate] 0.6 Nikkor SS-10 [Product name of sorbitan monostearate] 0.9 Ethyl alcohol 10.5 Purified water Total 30 ml Propellant dimethyl ether 70 ml Undiluted solution Each component of (1) was heated, mixed and stirred to make it uniform, and a stock solution was prepared, and then this stock solution was filled in an aerosol container together with a propellant to produce an aerosol agent.
【0011】実施例2,3及び比較例1〜3 表1に示す処方を用い、実施例1と同様の方法でエアゾ
ール剤を製造した。 比較例4 表1に示す処方を用いて原液を調製し、そのまま液剤と
して用いた。Examples 2 and 3 and Comparative Examples 1 to 3 Using the formulations shown in Table 1, an aerosol agent was produced in the same manner as in Example 1. Comparative Example 4 A stock solution was prepared using the formulation shown in Table 1 and used as it was as a liquid agent.
【0012】[0012]
【表1】 [Table 1]
【0013】試験例 (試験方法) 手の甲に直径5mmの穴を開けたゴム手袋を着用し、
ヒトスジシマカの入ったゲージに手を差し込む。 蚊1匹に吸血させる。 充分に吸血したら手を抜き、ゴム手袋を外す。 痒みの程度が耐えがたくなったら検体(実施例2,3
及び比較例1〜3で製造したエアゾール剤)を適量(3
cmの距離から1〜3秒)塗布する。また、比較例4で
製造した液剤は適量を塗布する。 塗布直後から、1分ごとに痒みの程度を自己判定(表
2参照)する。コントロールは痒みの程度が耐えられな
くなった時を0分とし、何も処置しない。Test Example (Test Method) Wear rubber gloves with a 5 mm diameter hole on the back of the hand,
Insert your hand into the gauge containing Aedes albopictus. Make one mosquito suck blood. When you have sufficiently sucked blood, remove your hands and remove the rubber gloves. If the degree of itching becomes unbearable, the sample (Examples 2 and 3)
And an appropriate amount of the aerosol agent produced in Comparative Examples 1 to 3 (3
Apply from a distance of 1 to 3 seconds). Further, the liquid agent produced in Comparative Example 4 is applied in an appropriate amount. Immediately after application, the degree of itching is self-determined every minute (see Table 2). The control is 0 minutes when the degree of itchiness becomes intolerable, and no treatment is performed.
【0014】[0014]
【表2】 [Table 2]
【0015】(結果)結果を被検者5人の平均値として
図1及び図2に示す。実施例2及び3で調製した本発明
のエアゾール剤では、痒みスコアのピークが1以下、す
なわちほとんど痒くない状態であり、生活者にとって有
効な痒み抑制効果が得られることがわかった。(Results) The results are shown in FIGS. 1 and 2 as an average value of five subjects. It was found that with the aerosol preparations of the present invention prepared in Examples 2 and 3, the pruritus score peak was 1 or less, that is, there was almost no pruritus, and an effective pruritus-suppressing effect for consumers was obtained.
【図面の簡単な説明】[Brief description of the drawings]
【図1】本発明のエアゾール剤及び比較例4の液剤の鎮
痒効果を示す図で、縦軸は痒みスコア、横軸は時間
(分)を表す。FIG. 1 is a diagram showing the antipruritic effect of the aerosol of the present invention and the liquid preparation of Comparative Example 4, in which the vertical axis represents the itch score and the horizontal axis represents the time (minutes).
【図2】本発明のエアゾール剤と比較するエアゾール剤
の鎮痒効果を示す図で、縦軸は痒みスコア、横軸は時間
(分)を表す。FIG. 2 is a graph showing the antipruritic effect of an aerosol agent compared with the aerosol agent of the present invention, in which the vertical axis represents the pruritus score and the horizontal axis represents time (minutes).
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 //(A61K 31/045 31:125) (72)発明者 木村 文紀 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内 (72)発明者 加藤 恵子 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification number Reference number within the agency FI technical display location // (A61K 31/045 31: 125) (72) Inventor Fumiki Kimura 3 Takada, Toshima-ku, Tokyo No. 24-1 Taisho Pharmaceutical Co., Ltd. (72) Inventor Keiko Kato 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.
Claims (3)
の(A)〜(C)の成分を配合した原液及び噴射剤から
なるエアゾール剤。 (A)ポリオキシエチレンソルビタン脂肪酸エステル類
及びソルビタン脂肪酸エステル類からなる群より選ばれ
る界面活性剤1種または2種以上 (B)メントール0.5〜8重量% (C)メントール1重量部に対して1〜0.5重量部の
カンフル1. An aerosol agent comprising a stock solution and a propellant in which the following components (A) to (C) are mixed in a mixed solvent of water and a lower alcohol. (A) one or more surfactants selected from the group consisting of polyoxyethylene sorbitan fatty acid esters and sorbitan fatty acid esters (B) menthol 0.5 to 8 wt% (C) to 1 part by weight of menthol 1 to 0.5 parts by weight camphor
量%以上で構成される請求項1記載のエアゾール剤。2. The aerosol composition according to claim 1, wherein the propellant has a dimethyl ether content of 80% by weight or more.
重量%である請求項1または2記載のエアゾール剤。3. The compounding amount of the propellant is 50 to 70 of the whole preparation.
The aerosol composition according to claim 1 or 2, which is contained in a weight percentage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8206774A JPH09110677A (en) | 1995-08-10 | 1996-08-06 | Aerosol preparation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7-204799 | 1995-08-10 | ||
JP20479995 | 1995-08-10 | ||
JP8206774A JPH09110677A (en) | 1995-08-10 | 1996-08-06 | Aerosol preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09110677A true JPH09110677A (en) | 1997-04-28 |
Family
ID=26514675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8206774A Pending JPH09110677A (en) | 1995-08-10 | 1996-08-06 | Aerosol preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH09110677A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056350A1 (en) * | 1997-06-13 | 1998-12-17 | Taisho Pharmaceutical Co., Ltd. | Aerosols |
-
1996
- 1996-08-06 JP JP8206774A patent/JPH09110677A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056350A1 (en) * | 1997-06-13 | 1998-12-17 | Taisho Pharmaceutical Co., Ltd. | Aerosols |
AU729680B2 (en) * | 1997-06-13 | 2001-02-08 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation |
US6231835B1 (en) | 1997-06-13 | 2001-05-15 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation for skin cooling |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5776430A (en) | Topical antimicrobial cleanser containing chlorhexidine gluconate and alcohol | |
JP4213211B2 (en) | Skin penetration enhancer and drug delivery system including the same | |
US5906808A (en) | Process of preparing a topical antimicrobial cleanser | |
US5990100A (en) | Composition and method for treatment of psoriasis | |
EP0957939B1 (en) | Use of an emulsifier system for increasing penetration flux of pharmaceutical agents | |
US20070048360A1 (en) | Pharmaceutical compositions with melting point depressant agents and method of making same | |
US20090098069A1 (en) | Transdermal, alcohol-free, pharmaceutical compositions | |
EA019760B1 (en) | Transdermal delivery system, method for transdermal administration and method of preparing transdermal delivery system | |
JP3487633B2 (en) | Skin disease treatment emulsion | |
AU2003228612A1 (en) | Pharmaceutical composition | |
EP1409022A1 (en) | Pharmaceutical vehicle | |
JP2555555B2 (en) | Antifungal topical formulation | |
MX2007015255A (en) | Method and composition for transdermal drug delivery. | |
JPS6272611A (en) | Skin external preparation | |
JP3038837B2 (en) | Aerosol for skin cooling | |
TWI363617B (en) | Low irritant adhesive dressing | |
JPH08291049A (en) | Nonaqueous oily ointment base material and ointment for skin external use | |
JPH09110677A (en) | Aerosol preparation | |
US6627663B2 (en) | Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method | |
JP4450545B2 (en) | Aerosol formulation | |
WO1997005858A1 (en) | Aerosol preparation | |
JP4176858B2 (en) | Aerosol formulation | |
JP4176859B2 (en) | Aerosol formulation | |
JP2005170913A (en) | Antifungal composition for external use | |
JP4545244B2 (en) | Ophthalmic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050712 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060407 |